In Plain English:
Chonluten is a three-amino-acid chain (glutamic acid – aspartic acid – glycine) originally derived from bronchial epithelial cells and developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. In cell studies it dials down inflammatory signals — particularly TNF-alpha and IL-6 — that are overactive in chronic bronchitis, COPD, and post-viral lung injury. It also upregulates protective enzymes (SOD, HSP70) and may interact directly with DNA to reset gene expression patterns that drift with age. The main human-use evidence comes from an uncontrolled observational study in COPD/chronic bronchitis patients and an unpublished sports-medicine report in elite athletes; no randomised controlled trials have been published. The capsule form sold by the Khavinson institute brand (Cytogens AC-7) contains the same amino acids blended with excipients, while research-grade lyophilised EDG is sold for laboratory use.
Research Maturity
Preclinical (~6–10 peer-reviewed papers (2006–2022), mostly in vitro; 1 observational study; no RCTs or independent replication+ Studies)
Focus
Immune Modulation
Respiratory Health
Origin
Developed at the St. Petersburg Institute of Bioregulation and Gerontology (Russia) by V.Kh. Khavinson; isolated as the putative active tripeptide of peptide complex AC-7 derived from bovine bronchial epithelial tissue. First described in the Khavinson bioregulator programme in the 1990s alongside Bronchogen (AEDL) as complementary bronchopulmonary bioregulators.
Mechanism
Modulates gene expression in bronchial epithelial and macrophage cells via proposed direct nuclear penetration and histone binding (H1, H2b, H3, H4 N-terminal motifs). Key targets: (1) suppresses TNF-alpha production in LPS-stimulated monocytes (THP-1 in vitro model, 2022); (2) reduces IL-6 expression in differentiated macrophages; (3) upregulates SOD (antioxidant defence) and HSP70 (stress protection); (4) downregulates COX-2 (prostaglandin synthesis); (5) modulates c-Fos immediate-early gene involved in cellular stress response; (6) reduces monocyte adhesion to activated endothelial cells; (7) proposed epigenetic action via DNA methylation modulation. Acts through partial STAT1 upregulation and hypothesised STAT3 attenuation, not classical receptor agonism.
Outcome
TNF-alpha production in LPS-stimulated monocytes (THP-1, in vitro inhibition), IL-6 expression in macrophages, monocyte-endothelial adhesion, SOD enzyme activity, HSP70 expression, c-Fos gene regulation; observational: symptom improvement in chronic bronchitis/COPD (combined Chonluten + Bronchogen oral course); athlete report: increased aerobic capacity, oxygen pulse, and respiratory reserve versus baseline.
